Fate Therapeutics Inc Stock Research

Market Summary

USD5.48+0.09

Market Closed

1.67%

FATE Alerts

Big jump in Revenue (Y/Y)
Losses in recent quarter

FATE Stock Price

FATE RSI Chart

FATE Valuation

Market Cap

533.2M

Price/Earnings (Trailing)

-1.89

Price/Sales (Trailing)

5.54

Price/Free Cashflow

-1.88

FATE Price/Sales (Trailing)

FATE Profitability

Return on Equity

-58.21%

Return on Assets

-39.93%

Free Cashflow Yield

-53.22%

FATE Fundamentals

FATE Revenue

Revenue (TTM)

96.3M

Revenue Y/Y

159.86%

Revenue Q/Q

196.08%

FATE Earnings

Earnings (TTM)

-281.7M

Earnings Y/Y

17.86%

Earnings Q/Q

32.55%

Price Action

52 Week Range

4.0243.12

(Low)(High)

Last 7 days

-1.4%

Last 30 days

-5.3%

Last 90 days

-46.3%

Trailing 12 Months

-85.6%

FATE Financial Health

Current Ratio

4.4

FATE Investor Care

Shares Dilution (1Y)

1.64%

Diluted EPS (TTM)

-2.91

Peers (Alternatives to Fate Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	126.4B	26.3B	1.33%	2.31%	19.3	4.8	1.32%	11.18%
GILD	99.2B	27.3B	-0.40%	40.80%	21.61	3.64	-0.09%	-26.23%
MRNA	57.1B	19.3B	6.53%	-10.59%	6.83	2.96	4.29%	-31.47%
BIIB	39.0B	10.2B	-0.01%	27.97%	12.8	3.83	-7.36%	95.80%
MID-CAP
NBIX	9.4B	1.5B	-5.27%	3.55%	60.62	6.29	31.34%	72.43%
DNLI	3.2B	108.5M	-10.19%	-29.91%	-9.71	29.17	122.90%	-12.19%
BEAM	2.2B	60.9M	-21.53%	-47.37%	-7.53	35.73	17.51%	22.00%
BBIO	2.2B	107.9M	22.92%	38.22%	-4.45	19.98	54.84%	17.36%
SMALL-CAP
RCUS	1.3B	112.0M	-3.60%	-50.92%	-4.82	11.49	-70.76%	-603.77%
REPL	1.1B	7.0M	-2.83%	20.33%	-6.95	155.42	131.81%	-45.39%
FATE	533.2M	96.3M	-5.35%	-85.58%	-1.89	5.54	72.44%	-32.79%
NVAX	524.0M	2.0B	-30.95%	-91.78%	-0.8	0.26	72.89%	62.27%
SGMO	290.2M	111.3M	-34.46%	-69.74%	-1.51	2.61	0.54%	-7.86%
VXRT	102.0M	107.0K	-5.82%	-84.77%	-0.95	953.19	-88.00%	-52.91%
IBIO	30.1M	-	102.50%	-80.56%	-0.37	3.21	0.51%	-185.61%

Financials for Fate Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	39.5%	96,300,000	69,013,000	68,257,000	63,120,000	55,846,000
Operating Expenses	5.8%	404,686,000	382,362,000	349,838,000	308,371,000	272,840,000
S&GA Expenses	5.8%	84,232,000	79,584,000	73,747,000	65,564,000	57,321,000
R&D Expenses	5.8%	320,454,000	302,778,000	276,091,000	242,807,000	215,519,000
Interest Expenses	-	0.00	-	-	-	-
Net Income	4.2%	-281,721,000	-293,979,000	-253,724,000	-232,752,000	-212,151,000
Net Income Margin	31.3%	-2.93	-4.26	-3.72	-3.69	-
Free Cahsflow	2.3%	-283,774,000	-290,370,000	-274,757,000	-257,194,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-5.8%	706	749	807	858	921
Current Assets	-6.2%	502	535	599	599	633
Cash Equivalents	-25.3%	61.00	82.00	55.00	65.00	134
Net PPE	0.8%	110	109	103	98.00	92.00
Current Liabilities	9.7%	114	104	92.00	78.00	81.00
Shareholder's Equity	-6.6%	484	518	580	633	679
Retained Earnings	-5.7%	-1,050	-994	-910	-834	-769
Additional Paid-In Capital	1.4%	1,536	1,516	1,495	1,471	1,449
Shares Outstanding	0.2%	97.00	97.00	97.00	97.00	96.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-2.1%	-248	-243	-221	-200	-162
Share Based Compensation	6.5%	79.00	74.00	68.00	61.00	54.00
Cashflow From Investing	-9.8%	167	185	182	141	-324
Cashflow From Financing	-17.1%	9.00	11.00	18.00	18.00	453

Risks for FATE

What is the probability of a big loss on FATE?

100%

Probability that Fate Therapeutics stock will be more than 20% underwater in next one year

98.1%

Probability that Fate Therapeutics stock will be more than 30% underwater in next one year.

32.7%

Probability that Fate Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FATE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for FATE

Cumulative Returns on FATE

16.8%

7-Year Cumulative Returns

-10.5%

5-Year Cumulative Returns

-37.2%

3-Year Cumulative Returns

What are the long-term rolling returns for FATE?

FIve years rolling returns for Fate Therapeutics.

Annualized Returns

Which funds bought or sold FATE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	unchanged	-	-542,130	444,000	-%
2023-03-17	American Portfolios Advisors	added	15.03	2,590	66,894	-%
2023-03-10	BAILLIE GIFFORD & CO	unchanged	-	-4,247	3,753	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-22.54	-14,316,600	7,666,400	0.01%
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-	-	-%
2023-03-03	TIAA, FSB	unchanged	-	-216,497	177,503	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-393,513	322,487	-%
2023-02-24	NATIXIS	new	-	28,968	28,968	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-40,000	-	-%
2023-02-17	Coppell Advisory Solutions Corp.	new	-	42,277	42,277	0.01%

Latest Funds Activity

Are funds buying FATE calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own FATE

No. of Funds

Fate Therapeutics News

Schedule 13G FIlings of Fate Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2023	millennium management llc	1.7%	1,696,431	SC 13G
Mar 10, 2023	vanguard group inc	10.12%	9,936,042	SC 13G/A
Feb 13, 2023	capital world investors	5.8%	5,591,517	SC 13G
Feb 09, 2023	vanguard group inc	8.20%	7,972,551	SC 13G/A
Feb 03, 2023	state street corp	6.11%	5,935,459	SC 13G
Jan 06, 2023	blackrock inc.	10.0%	9,725,895	SC 13G/A
Feb 09, 2022	ark investment management llc	10.80%	10,312,167	SC 13G/A
Feb 03, 2022	blackrock inc.	7.4%	7,060,552	SC 13G/A
Oct 12, 2021	fmr llc	-	0	SC 13G/A
Sep 10, 2021	ark investment management llc	11.34%	10,790,423	SC 13G

FATE Fair Value

Fate Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Fate Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	0.22 -95.99%	0.47 -91.42%	1.42 -74.09%	3.03 -44.71%	6.27 14.42%
Current Inflation	0.20 -96.35%	0.42 -92.34%	1.25 -77.19%	2.64 -51.82%	5.39 -1.64%
Very High Inflation	0.17 -96.90%	0.37 -93.25%	1.05 -80.84%	2.17 -60.40%	4.39 -19.89%

Historical Fate Therapeutics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Fate Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 22, 2023	SC 13G	Major Ownership Report
Mar 10, 2023	SC 13G/A	Major Ownership Report
Feb 28, 2023	10-K	Annual Report
Feb 28, 2023	8-K	Current Report
Feb 13, 2023	SC 13G	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 07, 2023	4	Insider Trading
Feb 07, 2023	4	Insider Trading
Feb 07, 2023	4	Insider Trading
Feb 07, 2023	4	Insider Trading

Latest Insider Trading transactions for FATE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-19	MENDLEIN JOHN	acquired	38,991	1.37	28,461	-
2023-01-13	MENDLEIN JOHN	bought	198,906	5.43	36,631	-
2023-01-12	Valamehr Bahram	acquired	579	1.37	423	chief r&d officer
2023-01-11	MENDLEIN JOHN	bought	499,232	5.67	88,048	-
2023-01-10	TAHL CINDY	sold	-60,537	5.24	-11,553	general counsel and secretary
2023-01-10	Wolchko J Scott	sold	-240,553	5.24	-45,907	president and ceo
2023-01-10	Plavsic Mark	sold	-17,910	5.24	-3,418	chief technical officer
2023-01-10	Dulac Edward J III	sold	-38,414	5.24	-7,331	chief financial officer
2023-01-10	Chu Yu-Waye	sold	-41,003	5.24	-7,825	chief medical officer
2023-01-10	Valamehr Bahram	sold	-57,205	5.24	-10,917	chief r&d officer

About Fate Therapeutics

J. Scott Wolchko

www.fatetherapeutics.com

450

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Collaboration revenue	$ 96,300	$ 55,846	$ 31,434
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 320,454	$ 215,519	$ 125,623
General and administrative	84,232	57,321	33,896
Total operating expenses	404,686	272,840	159,519
Loss from operations	(308,386)	(216,994)	(128,085)
Other income (expense):
Interest income	5,842	1,309	2,400
Change in fair value of stock price appreciation milestones	20,307	3,534	(47,702)
Other income	516	0	0
Total other income (expense), net	26,665	4,843	(45,302)
Net loss	(281,721)	(212,151)	(173,387)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities, net	(1,092)	(832)	48
Comprehensive loss	$ (282,813)	$ (212,983)	$ (173,339)
Earnings Per Share, Basic	$ (2.91)	$ (2.24)	$ (2.10)
Earnings Per Share Diluted	$ (2.91)	$ (2.24)	$ (2.10)
Weighted Average Number of Shares Outstanding, Basic	96,826,058	94,747,311	82,385,319
Weighted Average Number of Shares Outstanding, Diluted	96,826,058	94,747,311	82,385,319

FATE Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 61,333	$ 133,583
Accounts receivable	38,480	8,676
Short-term investments	374,894	482,327
Prepaid expenses and other current assets	27,367	8,826
Total current assets	502,074	633,412
Long-term investments	4,942	100,664
Property and equipment, net	110,020	91,529
Operating lease right-of-use assets	66,069	70,720
Restricted cash	15,227	15,227
Collaboration contract assets	7,196	9,870
Other assets	33	33
Total assets	705,561	921,455
Current liabilities:
Accounts payable	8,265	8,612
Accrued expenses	53,932	42,412
CIRM award liability, current portion	4,000	3,200
Deferred revenue, current portion	42,226	21,483
Operating lease liabilities, current portion	5,628	5,577
Total current liabilities	114,051	81,284
Deferred revenue, net of current portion	0	27,124
CIRM award liability, net of current portion	0	800
Operating lease liabilities, net of current portion	103,710	109,241
Stock price appreciation milestones, net of current portion	3,861	24,168
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized shares--5,000,000 at December 31, 2022 and December 31, 2021; Class A Convertible Preferred shares issued and outstanding--2,794,549 at December 31, 2022 and December 31, 2021	3	3
Common stock, $0.001 par value; authorized shares--250,000,000 at December 31, 2022 and December 31, 2021; issued and outstanding --97,294,917 at December 31, 2022 and 95,726,962 at December 31, 2021	97	96
Additional paid-in capital	1,536,497	1,448,584
Accumulated other comprehensive (loss) gain	(1,854)	(762)
Accumulated deficit	(1,050,804)	(769,083)
Total stockholders’ equity	483,939	678,838
Total liabilities and stockholders’ equity	$ 705,561	$ 921,455